Section Arrow
ATXS.NASDAQ
- Astria Therapeutics
Quotes are at least 15-min delayed:2025/05/25 15:15 EDT
Last
 3.92
-0.16 (-3.92%)
Day High 
4.03 
Prev. Close
4.08 
1-M High
5.47 
Volume 
245.44K 
Bid
3.7
Ask
4.64
Day Low
3.87 
Open
3.99 
1-M Low
3.6914 
Market Cap 
230.25M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 4.1 
20-SMA 4.51 
50-SMA 4.96 
52-W High 12.92 
52-W Low 3.555 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.88/-2.54
Enterprise Value
234.22M
Balance Sheet
Book Value Per Share
3.44
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
PLRZPolyrizon Ltd0.0034-0.0008-19.05%-- 
IMNNImunon1.16+0.7445+179.18%-- 
NCNANuCana plc0.038-0.0014-3.55%-- 
RXRXRecursion Pharmaceuticals4.08-0.065-1.57%-- 
KLTOKlotho Neurosciences Inc0.1923+0.0033+1.75%-- 
Quotes are at least 15-min delayed:2025/05/25 15:15 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.